This proposal focuses on the CHC22 isoform of clathrin, which is preferentially expressed in human skeletal muscle. Recent work from the laboratory indicates that CHC22 is involved in intracellular sequestration of the GLUT4 glucose transporter. Upon insulin stimulation of skeletal muscle and adipocytes, GLUT4 is released from the GLUT4 storage compartment (GSC) in vesicles that fuse with the plasma membrane, where it can import glucose in response to acute metabolic needs. Thus GLUT4 membrane traffic is critical for glucose metabolism and its disruption is associated with type 2 diabetes. The implication of CHC22 clathrin in GLUT4 membrane traffic in humans is interesting because CHC22 is missing from mice and CHC22 expression may therefore account for some of the known differences between glucose metabolism by humans and mice. This proposal aims to characterize the role that CHC22 plays in GLUT4 transport, to determine the molecular mechanisms that control CHC22 function and to explore polymorphisms in CHC22 that would affect its function and thereby contribute to incidence of type 2 diabetes.
For Aim 1, basic questions about CHC22-mediated membrane traffic of GLUT4 will be addressed, including molecular details of CHC22 function following insulin stimulation and its distribution in the muscle of diabetic patients. Experiments will compare GLUT4 membrane traffic in humans with its traffic in CHC22-transgenic mice. The presence and role of CHC22 in human adipocytes will also be investigated.
For Aim 2, the factors needed for CHC22 to function properly will be established using two assays for its function. Genetic screens will be designed to re-create a functional pathway for CHC22 when it is introduced in mouse cells and to dissect CHC22 function in GSC formation.
Aim 3 of this project is to characterize the biochemical properties of CHC22 that mediate its function. CHC22 protein will be purified from both tissue and recombinant sources to determine its morphology and whether it can assemble into macromolecular complexes. CHC22-associated proteins will be identified. Recombinant fragments of CHC22 protein will be expressed and their structure determined at crystallographic resolution.
Aim 4 is to determine the distribution of CHC22 polymorphisms within human populations for correlation with incidence of type 2 diabetes. The functional features of common CHC22 variants will be characterized. In addition, phylogenetic analysis of CHC22 will assess whether its function in different species is related to nutrition habits. With these aims the overall goal of this proposal is to further characterize the role that CHC22 plays in GLUT4 transport in order to understand how human glucose metabolism is regulated. While studies of mice have provided major insights into pathways relevant to type 2 diabetes, CHC22 represents a missing species-specific element. The research proposed here will establish novel characteristics of human glucose homeostasis and will enable development of better animal models for studying its dysfunction in diabetes.

Public Health Relevance

Recent findings reveal that the CHC22 clathrin protein plays a role in human glucose metabolism by influencing how muscle can respond to insulin and take up glucose. This protein is absent in mice and therefore represents a special aspect of human glucose metabolism that could have significance for elucidating mechanisms of type 2 diabetes. The proposed work will characterize the cell biology, biochemistry and genetics of the CHC22 protein to establish molecular details of its function and its relationship to human metabolic disease, and to provide information that will enable design of therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
High Priority, Short Term Project Award (R56)
Project #
1R56DK083589-01
Application #
7922790
Study Section
Cellular Aspects of Diabetes and Obesity Study Section (CADO)
Program Officer
Haft, Carol R
Project Start
2009-09-20
Project End
2011-08-31
Budget Start
2009-09-20
Budget End
2011-08-31
Support Year
1
Fiscal Year
2009
Total Cost
$386,250
Indirect Cost
Name
University of California San Francisco
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Dannhauser, Philip N; Camus, Stéphane M; Sakamoto, Kazuho et al. (2017) CHC22 and CHC17 clathrins have distinct biochemical properties and display differential regulation and function. J Biol Chem 292:20834-20844
Hoshino, Sachiko; Sakamoto, Kazuho; Vassilopoulos, Stéphane et al. (2013) The CHC22 clathrin-GLUT4 transport pathway contributes to skeletal muscle regeneration. PLoS One 8:e77787
Esk, Christopher; Chen, Chih-Ying; Johannes, Ludger et al. (2010) The clathrin heavy chain isoform CHC22 functions in a novel endosomal sorting step. J Cell Biol 188:131-44